^
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ibrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
acalabrutinib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
fludarabine oral
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
rituximab
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
cladribine
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
rituximab + bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
everolimus
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
ofatumumab
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
rituximab + carfilzomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
I-131-CLR1404
Sensitive
:
B
MYD88 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
C2
MYD88 L265P
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
venetoclax
Sensitive
:
C2
MYD88 mutation + CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib
Sensitive
:
C2
CXCR4 mutation
Waldenstrom Macroglobulinemia
BDR
Sensitive
:
C3
CXCR4 mutation
Waldenstrom Macroglobulinemia
rituximab + carfilzomib
Sensitive
:
C3
CXCR4 G336X
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
C3
CXCR4 S338X
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our